Rhythm Pharma says Japan regulator approves IMCIVREE for acquired hypothalamic obesity

• Rhythm Pharmaceuticals won Japan MHLW marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity.
• Launch targeted by end-2026, subject to final pricing.
• Approval backed by Phase 3 TRANSCEND data showing an 18.8% placebo-adjusted BMI reduction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240800PRIMZONEFULLFEED9814829) on August 24, 2026, and is solely responsible for the information contained therein.